Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIPEC, Apatinib, and S-1 for Gastric Cancer
NCT03428425Phase 2Unknown
- Sponsor
- Hebei Medical University
- Start
- Feb 2018
- Primary completion
- Dec 2018
01
Overview
A Phase 2 trial of Rivoceranib in gastric cancer (GC), sponsored by Hebei Medical University. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT03428425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03428425.